Abstract:INTRODUCTION As aggregation underpins Tau toxicity, aggregation inhibitor peptides may have disease‐modifying potential. They are therefore currently being designed and target either the 306VQIVYK311 aggregation‐promoting hotspot found in all Tau isoforms or the 275VQIINK280 aggregation‐promoting hotspot found in 4R isoforms. However, for any Tau aggregation inhibitor to potentially be clinically relevant for other tauopathies, it should target both hotspots to suppress aggregation of Tau isoforms, be stable, cross the blood‐brain barrier, and rescue aggregation‐dependent Tau phenotypes in vivo. METHODS We developed a retro‐inverso, stable D‐amino peptide, RI‐AG03 [Ac‐rrrrrrrrGpkyk(ac)iqvGr‐NH2], based on the 306VQIVYK311 hotspots which exhibit these disease‐relevant attributes. RESULTS Unlike other aggregation inhibitors, RI‐AG03 effectively suppresses aggregation of multiple Tau species containing both hotspots in vitro and in vivo, is non‐toxic, and suppresses aggregation‐dependent neurodegenerative and behavioral phenotypes. DISCUSSION RI‐AG03 therefore meets many clinically relevant requirements for an anti‐aggregation Tau therapeutic and should be explored further for its disease‐modifying potential for Tauopathies. Highlights Our manuscript describes the development of a novel peptide inhibitor of Tau aggregation, a retro‐inverso, stable D‐amino peptide called RI‐AG03 that displays many clinically relevant attributes. We show its efficacy in preventing Tau aggregation in both in vitro and in vivo experimental models while being non‐toxic to cells. RI‐AG03 also rescues a biosensor cell line that stably expresses Tau repeat domains with the P301S mutation fused to Cer/Clo and rescues aggregation‐dependent phenotypes in vivo, suppressing neurodegeneration and extending lifespan. Collectively our data describe several properties and attributes of RI‐AG03 that make it a promising disease‐modifying candidate to explore for reducing pathogenic Tau aggregation in Tauopathies such as Alzheimer's disease. Given the real interest in reducing Tau aggregation and the potential clinical benefit of using such agents in clinical practice, RI‐AG03 should be investigated further for the treatment of Tauopathies after validation in mammalian models. Tau aggregation inhibitors are the obvious first choice as Tau‐based therapies as much of Tau‐mediated toxicity is aggregation dependent. Indeed, there are many research efforts focusing on this therapeutic strategy with aggregation inhibitors being designed against one of the two aggregation‐promoting hotspots of the Tau protein. To our knowledge, RI‐AG03 is the only peptide aggregation inhibitor that inhibits aggregation of Tau by targeting both aggregation‐promoting hotspot motifs simultaneously. As such, we believe that our study will have a significant impact on drug discovery efforts in this arena.

Gene therapy using Aβ variants for amyloid reduction

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Simple improvements in vector design afford substantial gains in AAV delivery of aggregation-slowing Aβ variants

Small Interfering RNA Delivery to the Neurons Near the Amyloid Plaques for Improved Treatment of Alzheimer׳s Disease

Brain Targeting and Aβ Binding Bifunctional Nanoparticles Inhibit Amyloid Protein Aggregation in APP/PS1 Transgenic Mice.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Advances in Alzheimer's Disease-Associated Aβ Therapy Based on Peptide

Advances in Alzheimer’s Disease-Associated Aβ Therapy Based on Peptide

Therapeutic effects of a novel synthetic α-secretase

Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.

Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model

Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer’s disease alleviates amyloid-related pathologies in mice

Single chain variable fragment against aβ expressed in baculovirus inhibits abeta fibril elongation and promotes its disaggregation.

Modulation of Amyloid and Tau Aggregation to Alleviate Cognitive Impairment in a Transgenic Mouse Model of Alzheimer's Disease

Rescue of Cognitive Deficits in APP/PS1 Mice by Accelerating the Aggregation of Β-Amyloid Peptide

Peptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's disease

FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

P2-315: A Novel Biotherapy for the Treatment of Alzheimer's Disease

A novel peptide‐based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies

Systemic Treatment with siRNA Targeting Gamma-Secretase Activating Protein Inhibits Amyloid-β Accumulation in Alzheimer’s Disease